Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics, VivoMedica Launch Effort to Validate Cardiac Model

NEW YORK (GenomeWeb News) – Madison, Wis.-based Cellular Dynamics and Sittingbourne, England-based VivoMedica today said that they have launched a consortium to validate a human cell model and analysis system, based on the firms' technologies, for preclinical cardiotoxicity testing of drug candidates.

The firms said the consortium is being launched this week in France at the Safety Pharmacology Society 9th Annual Meeting. The firms hope to enlist pharmaceutical companies in validating the human cardiac model.

Specifically, the consortium aims to validate the testing system using Cellular Dynamics' iCell Cardiomyocytes and VivoMedica's DrugPrint analysis system. They said that extracellular micro-electrode array recordings from induced pluripotent stem cell-derived human cardiomyocytes will be analyzed using VivoMedica's electrical waveform analysis technology.

The partners believe this approach will identify drug-induced changes that indicate the arrhythmogenic potential of drug candidates under investigation.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.